Brief: Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

Filana Therapeutics

06/11/2023 14:27

Nov 6 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES COMPLETES ENROLLMENT FOR PIVOTAL PHASE 3
PROGRAM OF SIMUFILAM IN ALZHEIMER’S DISEASE
    * CASSAVA SCIENCES INC- TOP-LINE RESULTS FOR ON-GOING,
52-WEEK
PHASE 3 TRIAL EXPECTED APPROXIMATELY YEAR-END 2024
    * CASSAVA SCIENCES INC- TOP-LINE RESULTS FOR ON-GOING,
76-WEEK
PHASE 3 TRIAL EXPECTED APPROXIMATELY MID-YEAR 2025

Source text for Eikon:  ID:nGNX1CmtRF 
Further company coverage:  SAVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))